CVS takes a swing at Bristol Myers and Pfizer, excluding coverage of their megablockbuster Eliquis in 2022
Bristol Myers Squibb brought in more than $9 billion in sales from its anticoagulant Eliquis in 2020, and it continues to see growth with more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
